SGLT inhibitor adjunct therapy in type 1 diabetes

Diabetologia

Volumn 61, Issue 10, 2018, Pages 2126-2133

  McCrimmon, Rory J ^a   Henry, Robert R ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Diabetic ketoacidosis; GLP 1 receptor agonist; HbA1c; Hypoglycaemia; Insulin; Review; Sodium glucose cotransporter inhibitors; Type 1 diabetes; Weight

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSIDE; SLC5A1 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 1;

BODY WEIGHT; DIABETES CONTROL; DIABETIC PATIENT; DRUG SCREENING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SELF MONITORING; ANTAGONISTS AND INHIBITORS; DIABETIC KETOACIDOSIS; DRUG EFFECT; INTERNATIONAL COOPERATION; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; GLUCOSIDES; GLYCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INTERNATIONAL COOPERATION; MULTICENTER STUDIES AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 1;

EID: 85052122808     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4671-6     Document Type: Review

References (35)

1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
2. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
3. Beall C, Ashford ML, McCrimmon RJ (2012) The physiology and pathophysiology of the neural control of the counterregulatory response. Am J Phys Regul Integr Comp Phys 302:R215–R223
4. Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271–286
5. The DCCT Research Group (1988) Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 11:567–573
6. McKnight JA, Wild SH, Lamb MJ et al (2015) Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 32:1036–1050
7. Miller KM, Foster NC, Beck RW et al (2015) Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 38:971–978
8. Livingstone SJ, Levin D, Looker HC et al (2015) Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313:37–44
9. George P, McCrimmon RJ (2013) Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med 30:179–188
10. Edelman S, Garg S, Frias J et al (2006) A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29:2189–2195
11. Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A (2014) Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2:710–718
12. Hari Kumar KV, Shaikh A, Prusty P (2013) Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 100:e55–e58
13. Zhao Y, Yang L, Xiang Y et al (2014) Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 99:E876–E880
14. Mathieu C, Zinman B, Hemmingsson JU et al (2016) Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39:1702–1710
15. Petrie JR, Chaturvedi N, Ford I et al (2017) Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:597–609
16. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR (2010) The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53:809–820
17. Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–502
18. Luippold G, Klein T, Mark M, Grempler R (2012) Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 14:601–607
19. Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A (2015) Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes 8:121–127
20. Perkins BA, Cherney DZ, Partridge H et al (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480–1483
21. Pieber TR, Famulla S, Eilbracht J et al (2015) Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17:928–935
22. Henry RR, Rosenstock J, Edelman S et al (2015) Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38:412–419
23. Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38:2258–2265
24. Sands AT, Zambrowicz BP, Rosenstock J et al (2015) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38:1181–1188
25. Garg SK, Henry RR, Banks P et al (2017) Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377:2337–2348
26. Buse JB, Garg SK, Rosenstock J, Banks P, Sawhney S, Strumph P (2017) Twenty-four week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem 1). Diabetes 66(Suppl 1):A18 Abstract
27. Danne T, Cariou B, Banks P, Sawhney S, Strumph P (2017) 24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2). Diabetologia 60(Suppl 1):S87 185 (Abstract)
28. Dandona P, Mathieu C, Phillip M et al (2017) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5:864–876
29. Garg SK, Strumph P (2018) Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med 378:967–968
30. Patel NS, Van Name MA, Cengiz E et al (2017) Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol Ther 19:618–622
31. 1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia 55:2356–2360
32. Cherney DZ, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28
33. Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321
34. Thrailkill KM, Nyman JS, Bunn RC et al (2017) The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 94:141–151
35. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657